MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1016/j.euo.2022.06.008

Медицинская библиотека · European urology oncology · 2022

Stereotactic Ablative Radiation for Systemic Therapy-naïve Oligometastatic Kidney Cancer.

Hannan Raquibul, Christensen Michael, Christie Alana, Garant Aurelie, Pedrosa Ivan, Robles Liliana, Mannala Samantha, Wang Chiachien, Hammers Hans, Arafat Waddah, Courtney Kevin, Bowman Isaac A, Sher David, Ahn Chul, Cole Suzanne, Choy Hak, Timmerman Robert, Brugarolas James

СтатьяПоддержка исследования: вне правительства СШАПоддержка NIH: внешняя программаПеревод в очереди

Аннотация

BACKGROUND

Evidence-based guidelines for the management of systemic therapy-naïve oligometastatic renal cell carcinoma (RCC) are lacking.

OBJECTIVE

To evaluate the potential of stereotactic ablative radiotherapy (SAbR) to provide longitudinal disease control while preserving quality of life (QOL) in patients with systemic therapy-naïve oligometastatic RCC.

DESIGN, SETTING, AND

PARTICIPANTS

RCC patients with three or fewer extracranial metastases were eligible. SAbR was administered longitudinally to all upfront and, as applicable, subsequent metastases.

OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: This prospective phase II single-arm trial was powered to achieve a primary objective of freedom from systemic therapy for >1 yr in >60% of patients (using the Clopper and Pearson methodology). Secondary endpoints included progression-free survival (PFS), defined as the time from first SAbR to progression not amenable to SAbR (local failure at SAbR-treated sites, new metastases not amenable to SAbR, more than three new metastases, or brain metastases); patient-reported QOL metrics; local control (LC) rates; toxicity; cancer-specific survival (CSS); and overall survival (OS).

RESULTS AND LIMITATIONS: Twenty-three patients received SAbR to 33 initial and 57 total sites. The median follow-up was 21.7 mo (interquartile range 16.3-30.3). Exceeding the prespecified 60% benchmark, freedom from systemic therapy at 1 yr was 91.3% (95% confidence interval [CI]: 69.5, 97.8). One-year PFS was 82.6% (95% CI: 60.1, 93.1). QOL was largely unaffected. LC was 100%. There were no grade 3/4 toxicities, but there was one death due to immune-related colitis 3 mo after SAbR while on subsequent checkpoint inhibitor therapy, where a SAbR contribution could not be excluded. One-year OS was 95.7% (95% CI: 72.9, 99.4); one-year CSS was 100%.

CONCLUSIONS

SAbR for oligometastatic RCC was associated with meaningful longitudinal disease control while preserving QOL. These data support further evaluation of SAbR for systemic therapy-naïve oligometastatic RCC.

PATIENT SUMMARY: Sequential stereotactic radiation therapy can safely and effectively control metastatic kidney cancer with limited spread for over a year without compromising patients' quality of life.

Для цитирования: Hannan Raquibul, Christensen Michael, Christie Alana, Garant Aurelie, Pedrosa Ivan, Robles Liliana, Mannala Samantha, Wang Chiachien, Hammers Hans, Arafat Waddah, Courtney Kevin, Bowman Isaac A, Sher David, Ahn Chul, Cole Suzanne, Choy Hak, Timmerman Robert, Brugarolas James. Stereotactic Ablative Radiation for Systemic Therapy-naïve Oligometastatic Kidney Cancer.. European urology oncology. 2022. DOI: 10.1016/j.euo.2022.06.008.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.